Triumvira Presents Data on T Cell Antigen Coupler (TAC) Technology at the 6th Annual Immuno-Oncology Summit

August 30, 2018

TAC technology shows efficacy, safety, and TAC-T cell persistence in preclinical models of liquid and solid tumors

AUSTIN, TX, and HAMILTON, ON, August 30, 2018Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on designing safe and more effective T cell therapies, will present data today on its novel T cell therapy technology, TAC-T, during an oral presentation in the Adoptive T Cell Therapies session of the 6th Annual Immuno-Oncology Summit held in Boston. The presentation will describe the differentiated mechanism of action of the company’s T cell antigen coupler (TAC) technology in preclinical studies demonstrating strong efficacy in both solid and liquid tumors with an improved safety profile compared to traditional CAR-T approaches.

The oral presentation, entitled: TAC-T: a novel T cell therapy, co-opts the endogenous T cell receptor for effective, safe, and persistent tumor rejection, will be delivered by Christopher Helsen, PhD, Director of Research and Development at Triumvira. Results from pre-clinical studies with human T cells engineered with Triumvira’s proprietary TAC technology directed against different antigens will be presented. The data suggest that TAC-T cells destroy tumor cells via a mechanism that mimics the natural process of T cell activation. Results clearly demonstrate efficient infiltration and proliferation in solid tumors resulting in rapid and sustained tumor regression in mice without toxicity. Furthermore, in a xenograft model of multiple myeloma, treated mice showed resistance to tumor re-challenge indicating long-term persistence of TAC-T cells.

“These results will further illustrate the potential of TAC-T cells, both in terms of efficacy and safety but also with respect to TAC T-cell persistence, a key point under consideration in T cell therapy,” said Paul Lammers, MD, MSc, President and Chief Executive Officer.

Triumvira also announces it is participating in the 11th Annual International Partnering Conference BioPharm America on September 5-6 and the 4th Annual CAR-TCR Summit 2018 – Changing Lives with CAR-T & TCR Cell Immunotherapies on September 4-5, both being held during Biotech Week Boston. For more information, or to set up a meeting with Triumvira at either conference email:

About Triumvira Immunologics
Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment bank, with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with either solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, and our research facilities in Hamilton, Ontario. For more information, visit or send email inquiries to

For more information:
Katie Gallagher
Phone: +1-617-374-8800, Ext. 109

[/et_pb_text][et_pb_text _builder_version=”3.12.2″]

BCMA-TAC cells induce remission/ show persistence in Multiple Myeloma xenograft model (KMS11-NanoLuc)

click image for larger version